Schizophrenia Research Forum - A Catalyst for Creative Thinking
Home Profile Membership/Get Newsletter Log In Contact Us
 For Patients & Families
What's New
Recent Updates
SRF Papers
Current Papers
Search All Papers
Search Comments
Research News
Conference News
Plain English
Current Hypotheses
Idea Lab
Online Discussions
Virtual Conferences
What We Know
Animal Models
Drugs in Trials
Research Tools
Community Calendar
General Information
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
SRF Team
Advisory Board
Support Us
How to Cite
Fan (E)Mail
The Schizophrenia Research Forum web site is sponsored by the Brain and Behavior Research Foundation and was created with funding from the U.S. National Institute of Mental Health.
Research News
back to News Search
Could New Hormone Compete With the Treadmill?

Adapted from a story that originally appeared on the Alzheimer Research Forum.

20 January 2012. Although it might not make people buff, a newly identified hormone may trigger some of the benefits of exercise, according to a study published in Nature online on January 11. A research team lead by Bruce Spiegelman and first author Pontus Boström at the Dana-Farber Cancer Institute in Boston found that when people exercise for sustained periods, their muscles release a hormone, which they called irisin, into the blood. “It is interesting that people would produce a hormone in response to exercise,” said Suzanne De La Monte at Brown University in Providence, Rhode Island, who was not involved in the study. When the researchers gave irisin to mice, it increased the conversion of white adipose tissue to the more energy-efficient brown version, and improved glucose tolerance in mice fed a high-fat diet.

Although the study only focused on the effects of irisin on fat, the hormone may have therapeutic application for a host of ailments, said Spiegelman. “We are very interested in the potential effects on other conditions that respond to exercise,” he explained. “We would like to know whether people with those conditions, who are not able to exercise, could benefit from irisin.” Others caution that these are still early days in this research. “When leptin was first discovered, we thought that it would cure obesity, but it turned out that obese people already produce a lot of leptin,” said De La Monte. “We don’t yet know the relevance of irisin production in humans.”

The road to the irisin discovery started in 2009 when Spiegelman and collaborators published that transgenic mice expressing the transcription factor PGC-1α in muscle cells were resistant to age-related obesity and diabetes (Wenz et al., 2009). PGC-1α activates peroxisome proliferator-activated receptor γ (PPARγ), a well-studied mediator of glucose metabolism. A number of drugs targeting PPARγ are being tested for the treatment of diabetes as well as for Alzheimer’s disease, but without much success.

In this study, Boström, Spiegelman, and colleagues found that, over a three-week period, normal mice that spent time on the running wheel or doing repeated bouts of swimming converted more subcutaneous white adipose tissue to brown adipose tissue than did controls. Unlike white adipose tissue, which stores extra calories as fat, brown adipose tissue burns it off. Researchers have long been looking for ways to boost the conversion of white-to-brown fat cells as a therapeutic treatment for obesity and related disorders. Boström, found that the same white-to-brown fat conversion occurred in transgenic mice expressing high levels of PGC-1α in their muscles, without the need for exercise. This suggested that muscle PGC-1α, which is naturally triggered by exercise, might be sending some kind of signal to fat cells to change.

The researchers looked for muscle genes induced by PGC-1α. They found several, but the product of only one, FNDC5, triggered the conversion of white adipocytes to brown when applied to cells in culture. Further biochemical analysis revealed that after FNDC5 is produced in muscle cells, a fragment of the protein is cleaved off and released into the blood. Spiegelman called this polypeptide irisin after Iris, the Greek messenger goddess. After mice spent three weeks running on a wheel, their irisin blood levels increased by 65 percent. To see if the mouse data have any human relevance, Boström, tested volunteers doing endurance training. After 10 weeks, they also showed increased blood irisin.

Boström and Spiegelman suspected that it might be irisin that sends the “exercise message” from muscle to other tissues in the body. To test this, they injected an adenovirus vector carrying full-length FNDC5 into normal mice. Plasma levels of irisin increased three- to fourfold in these animals, similar to the increase seen in mice after exercise. Ten days later, the mice had more brown adipose tissue and a very slight decrease in weight. When the adenovirus was given to mice fed a high-fat diet, irisin caused a significant improvement in glucose tolerance, and fasting insulin was reduced. On the other hand, when normal mice were injected with anti-FNDC5 antibodies before they swam, the normally observed effects of exercise on adipose tissue were toned down.

Although brown fat is supposed to use up more energy than white fat, increasing irisin production only had a modest effect on the weight of the mice. But giving the hormone for more than 10 days could have a more profound effect, said Spiegelman. (Ten days was about as long as the irisin expression from the adenovirus lasted.) “We have now made a more stable form of the hormone that we can give directly to mice to look at chronic administration,” he added. Such results will be critical to evaluating the potential for irisin as a therapy.

The current study did not examine cognition, and it is not known whether irisin even enters the brain, but if it does, it might help explain some of the beneficial effects of exercise on cognition and dementia. But, said Spiegelman, “We are very interested in that aspect.” This possibility intrigued Suzanne Craft of the University of Washington School of Medicine, Seattle. “There is good evidence that exercise has very potent effects on the brain from many perspectives; this may be one of those mechanisms,” she told ARF. One of Spiegelman’s earlier studies reported that mice deficient in PGC-1α exhibit many of the symptoms of Huntington’s disease, suggesting that the transcription factor might play a role in the nervous system (see Lin et al., 2004). A more recent study revealed that activating PGC-1α could slow the course of Parkinson’s disease (see Zheng et al., 2010).—Laura Bonetta.

Boström P, Wu J, Jedrychowski MP, Korde A, Ye L, Lo JC, Rasbach KA, Boström EA, Choi JH, Long JZ, Kajimura S, Zingaretti MC, Vind BF, Tu H, Cinti S, Højlund K, Gygi SP, Spiegelman BM. A PGC-1α-dependent Myokine That Drives Brown-fat-like Development of White Fat and Thermogenesis. Nature. 2012 Jan 11. Abstract

Submit a Comment on this News Article
Make a comment on this news article. 

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name  
*Last Name  
Country or Territory  
*Login Email Address  
*Confirm Email Address  
*Confirm Password  
Remember my Login and Password?  
Get SRF newsletter with recent commentary?  
Enter the code as it is shown below:
This code helps prevent automated registrations.

I recommend the Primary Papers

Please note: A member needs to be both registered and logged in to submit a comment.


(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)


SRF News
SRF Comments
Text Size
Reset Text Size
Copyright © 2005- 2016 Schizophrenia Research Forum Privacy Policy Disclaimer Disclosure Copyright